Regeneron Pharmaceuticals (REGN) Intangibles (2021 - 2026)

Regeneron Pharmaceuticals' Intangibles history runs 6 years deep, the most recent figure standing at $1.3 billion for Q2 2026.

• In Q2 2026, Intangibles rose 745.03% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $1.3 billion (up 745.03% YoY), while the FY2025 annual figure was $1.3 billion, up 9.47% from the prior year.
• Intangibles for Q2 2026 stood at $1.3 billion, up from $1.3 billion in the prior quarter.
• The five-year high for Intangibles was $1.4 billion in Q3 2025, with the low at $155.0 million in Q2 2025.
• The 5-year median for Intangibles is $1.1 billion (2024), against an average of $1.0 billion.
• The sharpest annual moves came in 2022 and 2025: Intangibles soared 13564.18% in 2022, then sank 85.94% in 2025.
• Regeneron Pharmaceuticals' Intangibles stood at $915.5 million in 2022, then increased by 13.45% to $1.0 billion in 2023, then grew by 10.59% to $1.1 billion in 2024, then advanced by 9.47% to $1.3 billion in 2025, then rose by 4.17% to $1.3 billion in 2026.
• Business Quant data shows REGN's Intangibles at $1.3 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.3 billion in Q4 2025.